-
Osobe Vidi sve
@PharmaScrip Scrip goes beyond the headlines and focuses on delivering insight & analysis on the whole of the drug discovery, development and product life cycle value chain.
Global
-
PharmaScrip: Biogen's Tecfidera Safe Following IPR Decision – For Now http://bit.ly/31zygI6
#PharmaScrip http://dlvr.it/RPVkR0 pic.twitter.com/BnP7YrsMnk
-
PharmaScrip: Executives On The Move: Bayer Names Upcoming Information Chief And Legal Hires At Eli Lilly And CytoDyn http://bit.ly/2H0g1St
#PharmaScrip http://dlvr.it/RPVkX1 pic.twitter.com/niPKgef8vl
-
Best Practices In Seasonal Vaccine Efficacy Studies: Tips For Successful Planning And Execution http://bit.ly/382paG0
#PharmaScrip -
PharmaScrip: Merck: It’s Not Just Keytruda Driving Future Growth http://bit.ly/2UFjsX1
#PharmaScrip http://dlvr.it/RPVBK0 pic.twitter.com/DlYWy2WyPf
-
PharmaScrip: Merck To Spin Out A New Company, Following Industry's Downsizing Trend http://bit.ly/372zKeX
#PharmaScrip http://dlvr.it/RPVBGg pic.twitter.com/SqTr2OVamp
-
PharmaScrip: Zydus Cadila Explores Orphan Drug Indication For NASH Candidate http://bit.ly/2Uva3AU
#PharmaScrip http://dlvr.it/RPVkW0 pic.twitter.com/gM8lcFIcGw
-
PharmaScrip: Novo Nordisk’s Positive Q4 Update Highlights Pipeline Plans http://bit.ly/2S0GbL5
#PharmaScrip http://dlvr.it/RPSgrJ pic.twitter.com/LSwVBlQ9ws
-
Pharma Is Priority As GSK Confirms Split With Consumer http://bit.ly/398w9gM
#PharmaScrip -
PharmaScrip: Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell http://bit.ly/31xD40C
#PharmaScrip http://dlvr.it/RPS985 pic.twitter.com/S4FB2qNe7S
-
PharmaScrip: Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits http://bit.ly/2SkGcIT
#PharmaScrip http://dlvr.it/RPRYLb pic.twitter.com/GsFF19lJuh
-
PharmaScrip: Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis http://bit.ly/2vSg5l3
#PharmaScrip http://dlvr.it/RPRYJ5 pic.twitter.com/xaAYOhR4uV
-
PharmaScrip: Coronavirus Notebook: Regeneron, HHS To Develop Antibody http://bit.ly/2RZfJS7
#PharmaScrip http://dlvr.it/RPQyns pic.twitter.com/U7sT0evqZr
-
PharmaScrip: Ranitidine Recall Dents GSK India, Which Mulls Plant Sale http://bit.ly/36ZNHu7
#PharmaScrip http://dlvr.it/RPQynn pic.twitter.com/5OwKhsQh0n
-
PharmaScrip: Japan Pharma Unconcerned About Virus Impact - For Now http://bit.ly/31wqyyb
#PharmaScrip http://dlvr.it/RPQymx pic.twitter.com/5EzMN49Pi3
-
PharmaScrip: Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out http://bit.ly/398npHt
#PharmaScrip http://dlvr.it/RPQQlt pic.twitter.com/2u5cZnAUvp
-
PharmaScrip: Freeline Bags Alnylam's Heggie As CEO http://bit.ly/37YdZON
#PharmaScrip http://dlvr.it/RPNy8p pic.twitter.com/x3eG36fbzl
-
PharmaScrip: Sanofi Q4 Preview: CEO Hudson’s Planned Revamp Key Focus http://bit.ly/31rBzAX
#PharmaScrip http://dlvr.it/RPNy6F pic.twitter.com/B8WwqIBNNY
-
PharmaScrip: Insmed Goes Full Steam Ahead With Bronchiectasis Candidate http://bit.ly/39dBQu5
#PharmaScrip http://dlvr.it/RPNSrp pic.twitter.com/t0xs0Tgl4i
-
PharmaScrip: United Therapeutics' Unituxin Disappoints In SCLC http://bit.ly/37ZjgFN
#PharmaScrip http://dlvr.it/RPMtCB pic.twitter.com/tB3FMmE52S
-
PharmaScrip: Podcast: Key Takeaways From J.P. Morgan http://bit.ly/2RVz9qY
#PharmaScrip http://dlvr.it/RPMt2J pic.twitter.com/Dn3le221D2
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.